Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies desi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Kellner, Christian, Peipp, Matthias, Gramatzki, Martin, Schrappe, Martin, Schewe, Denis M.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Point of View
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136853/
https://ncbi.nlm.nih.gov/pubmed/30221037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1448331
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items